Recent increase in antibiotic-resistant microorganisms in patients with spontaneous bacterial peritonitis adversely affects the clinical outcome in Korea

Journal of Gastroenterology and Hepatology (Australia)

Volumn 18, Issue 8, 2003, Pages 927-933

  Park, Young Hwan ^a   Lee, Han Chu ^a   Song, Hee Gon ^a   Jung, Saera ^a   Ryu, Soo Hyung ^a   Shin, Jung Woo ^a   Chung, Young Hwa ^a   Lee, Yung Sang ^a   Suh, Dong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Liver cirrhosis; Microbial drug resistance; Peritonitis

Indexed keywords

BETA LACTAMASE; CEFOTAXIME; CIPROFLOXACIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL OVERGROWTH; BACTERIAL PERITONITIS; BACTERIUM ISOLATION; FEMALE; GRAM NEGATIVE BACTERIUM; HOSPITALIZATION; HUMAN; KOREA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STRAIN DIFFERENCE; TREATMENT FAILURE;

EID: 0041352323     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2003.03086.x     Document Type: Article

References (28)

1. Llovet JM, Planas R, Morillas R et al. Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis: multivariate study. Am. J. Gastroenterol. 1993; 88: 388-92.
2. Guarner C, Sola R, Soriano G et al. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology 1999; 117: 414-19.
3. Navasa M, Rimola A, Rodes J. Bacterial infections in liver disease. Semin. Liver Dis. 1997; 17: 323-33.
4. Such J, Runyon BA. Spontaneous bacterial peritonitis. Clin. Infect. Dis. 1998; 27: 669-76.
5. Novella M, Sola R, Soriano G et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997; 25: 532-6.
6. Aparicio JR, Such J, Pascual S et al. Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences. J. Hepatol. 1999; 31: 277-83.
7. Ortiz J, Vila MC, Soriano G et al. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients. Hepatology 1999; 29: 1064-9.
8. Guarner C, Soriano G. Spontaneous bacterial peritonitis. Semin. Liver Dis. 1997; 17: 203-17.
9. Yoo J-H. Resistance profile of aerobic Gram-negative bacilli: extended spectrum β-lactamase, quinolone- and carbapenem-resistance. J. Korean Soc. Chemother. 1997; 15: 219-25.
10. Toledo C, Salmeron JM, Rimola A et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993; 17: 251-7.
11. Navasa M, Follo A, Llovet JM et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996; 111: 1011-17.
12. Dupeyron C, Campillo B, Mangeney N, Richardet J-P, Leluan G. Changes in nature and antibiotic resistance of bacteria causing peritonitis in cirrhotic patients over a 20 year period. J. Clin. Pathol. 1998; 51: 614-16.
13. Boixeda D, De Luis DA, Aller R, De Argila MD. Spontaneous bacterial peritonitis: clinical and microbiological study of 233 episodes. J. Clin. Gastroenterol. 1996; 23: 275-9.
14. Runyon BA, Hoefs JC. Culture-negative neutrocytic ascites: a variant of spontaneous bacterial peritonitis. Hepatology 1984; 4: 1209-11.
15. Runyon BA, Hoefs JC. Spontaneous vs. secondary bacterial peritonitis. Differentiation by response of ascitic fluid neutrophil count to antimicrobial therapy. Arch. Intern. Med. 1986; 146: 1563-5.
16. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A6. Wayne, Pennsylvania: National Committee for Clinical Laboratory Standards, 1997.
17. Rimola A, Tsao GG, Navasa M et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J. Hepatol. 2000; 32: 142-53.
18. Felisart J, Rimola A, Arroyo V et al. Cefotaxime is more effective than ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985; 5: 457-62.
19. Runyon BA, Mchutchison JG, Antillon MR et al. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology 1991; 100: 1737-42.
20. Ariza J, Xiol X, Esteve M et al. Aztreonam vs cefotaxime in the treatment of gram-negative spontaneous bacterial peritonitis in cirrhotic patients. Hepatology 1991; 14: 91-8.
21. Rimola A, Salmeron JM, Clemente G et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study. Hepatology 1995; 21: 674-9.
22. Silvain C, Breux JP, Grollier G et al. [Can septicemia and ascitic fluid infections in cirrhotic patients be treated by the oral route alone?] Gastroenterol. Clin. Biol. 1989; 13: 335-9 (In French).
23. Lee KW, Cho SR, Lee CS, Chong YS, Kwon OH. Prevalence of extended broad-spectrum β-lactamase in Escherichia coli and Klebsiella pneumoniae. Korean J. Infect. Dis. 1994; 26: 341-8.
24. Jeong SH, Song XX, Shin HB et al. Epidemiological study on extended-spectrum β-lactamase producing Klesiella pneumoniae infections by pulsed-field gel electrophoresis. Korean J. Infect. Dis. 1996; 28: 405-12.
25. Lewis MT, Gales AC, Sader HS, Pfaller MA, Jones RN. Frequency of occurrence and antimicrobial susceptibility patterns for pathogens isolated from Latin American patients with a diagnosis of pneumonia: results from the SENTRY antimicrobial surveillance program (1998). Diagn. Microbiol. Infect. Dis. 2000; 37: 63-74.
26. Chong YS, Lee KW, Suh JT et al. Antimicrobial resistance of aerobic gram-negative bacilli in different sizes of hospitals in Korea. Korean J. Infect. Dis. 1996; 28: 131-41.
27. Fernandez J, Navasa M, Gomez J et al. Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35: 140-8.
28. Navasa M, Follo A, Filella X et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998; 27: 1227-32.